A fascinating study published in 2018 found patients suffering from cancer-related fatigue displayed significant improvement ...

Popular for its stimulating and pain-relieving properties, the herb kratom can be as easy to buy as a bag of chips in many parts of the U.S. That’s also raised questions about whether kratom should be ...

Sulforaphane, a compound found in broccoli sprouts, may help lower blood sugar levels in people with prediabetes, a new study ...

Real Housewives of New Jersey star Dolores Catania has reached her high school weight after two years on the medication. She ...

Acute respiratory infections (ARIs) are a common cause of illness in children younger than 16 years and adults older than 65 ...

The FDA has approved Ctexli for the treatment of cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease, in ...

MSM supplements may help with joint pain and swelling, but some experts aren't convinced. What you should know about how they ...

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustain ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some promising results.

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...